A phase I, randomized, ascending‐dose study to assess safety, pharmacokinetics, and activity of GDC‐8264, a RIP1 inhibitor, in healthy volunteers

• Published in: Clinical and translational science Vol. 16; no. 10; pp. 1997 - 2009
• Main Authors: Jones, Nicholas S., Kshirsagar, Smita, Mohanan, Vishnu, Ramakrishnan, Vidya, Di Nucci, Flavia, Ma, Ling, Mao, Jialin, Ding, Hao, Klabunde, Sha, Vucic, Domagoj, Pan, Lin, Lekkerkerker, Annemarie N., Chen, Yuan, Rothenberg, Michael E.
• Format: Journal Article
• Language: English
• Published: Hoboken John Wiley and Sons Inc 01.10.2023; Wiley

Receptor‐interacting protein 1 (RIP1) is a key regulator of multiple signaling pathways that mediate inflammatory responses and cell death. RIP1 kinase activity mediates apoptosis and necroptosis induced by tumor necrosis factor (TNF)‐α, Toll‐like receptors, and ischemic tissue damage. RIP1 has been...